Truist Securities Reiterates Buy Rating on Intellia (NTLA) Following ONK Collaboration, The Deal Leverages NTLA's Genome Editing Expertise
Tweet Send to a Friend
Truist Securities analyst Joon Lee reiterated a Buy rating and $160.00 price target on Intellia Therapeutics (NASDAQ: NTLA) following the ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
